Skip to content

Heart Function in HIV-Negative Children Exposed to HIV and HAART

Left Ventricular Function in HIV-Negative Children Exposed to HIV and HAART In Utero

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01107834
Enrollment
60
Registered
2010-04-21
Start date
2010-05-31
Completion date
2011-12-31
Last updated
2016-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV, heart function, HAART, in utero, children

Brief summary

HIV-uninfected children born to HIV+ women have low level heart problems at birth which may predispose them to heart failure, arrythmias and heart attack later in life. The impact of these heart problems on future heart health is unclear as it is unknown if heart problems in these children persist, worsen or resolve in pre-pubescence. The objective of this study is to characterize heart function in HIV-negative pre-pubertal children born to HIV+ women and exposed to HIV and HAART in utero and compare them to age and gender matched healthy children born to HIV-negative women. Through this objective we will determine if heart problems in HIV-negative children born to HIV+ women and exposed to HAART in utero persists, worsens, or resolves during pre-pubescence.

Detailed description

Significance: Approximately 700,000 children annually are born to HIV-infected mothers throughout the world, but with the advent of perinatal highly active antiretroviral therapy (HAART), the majority of children are born uninfected in Westernized nations and those uninfected are increasing in developing nations. Uninfected children exposed to HIV and HAART in utero, have subclinical left ventricular dysfunction (LVD) at birth which may predispose them to heart failure, conduction abnormalities and myocardial infarction later in life. The impact of this LVD on future cardiac risk is unclear as it is unknown if LVD in these children persist, worsen or resolve in pre-pubescence. Study objectives: The objective of this study is to characterize left ventricular function in HIV-negative pre-pubertal children born to HIV+ women and exposed to HIV and HAART in utero and compare them to age and gender matched healthy children born to HIV-negative women. Through this objective we will determine if LVD in HIV-negative children born to HIV+ women and exposed to HAART in utero persists, worsens, or resolves during pre-pubescence. If LVD persists or worsens in pre-pubescence, these data will lead to future studies examining mechanisms of and treatments for LVD in these children and will significantly impact the clinical monitoring and care of these children. If LVD resolves during pre-pubescence, then these data will provide important information that clinical cardiac monitoring may not be critical in this population. Methods: We plan to examine left ventricular function in 30 HIV-negative children born to HIV+ women and exposed to HAART in utero and compare them to 30 healthy age and gender matched children born to HIV-negative women. Left ventricular function will be examined by 2-D, Doppler and Tissue Doppler imaging echocardiography using a General Electric Vivid 7® ultrasound machine. Left ventricular measures will include left ventricular structure and dimensions, systolic and diastolic flow rates, wall velocities during systole and diastole and systolic and diastolic strain and strain rates (sensitive measures of myocardial contractility). Echocardiographic measures will take place in the Cardiovascular Imaging Laboratory (CVIL) at Washington University School of Medicine by a certified cardiac ultrasonographer and data will be processed, analyzed and interpreted by the ultrasonographer, a consulting cardiologist and the principal investigator. Outcomes: Primary outcomes will include measures of left ventricular function: left ventricular mass, left ventricular end diastolic dimension, fractional shortening, systolic and diastolic wall velocities (tissue Doppler imaging) and systolic and diastolic strain and strain rates (2-D speckle tracking methodology).

Interventions

None listed

Sponsors

GlaxoSmithKline
CollaboratorINDUSTRY
Washington University School of Medicine
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
5 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

1. Age 5-12 years 2. Tanner stage I-III 3. Born to HIV+ mother 4. No HIV infection 5. Had taken standard of care prophylactic HAART at birth-1 month of age 6. Child currently not taking medications or have medical diagnosis that would affect left ventricular function 7. Mother was taking HAART during pregnancy (standard of care) 8. Mother was not using illegal drugs during pregnancy 9. No intrauterine growth restriction diagnosis during pregnancy 10. During pregnancy, mother will not have a diagnosis of type 2 diabetes or gestational diabetes.

Exclusion criteria

1. Age 5-12 years 2. Tanner stage I-III 3. Born to HIV-negative mother 4. Mother was not a frequent exerciser during pregnancy (\>2x/week) 5. Mother will not have gestational diabetes or a diagnosis of type 2 diabetes during pregnancy of the child being studied 6. Child currently not taking medications or have medical diagnosis that would affect left ventricular function

Design outcomes

Primary

MeasureTime frameDescription
Left Ventricular Mass IndexBaselineleft ventricular mass index measured by 2D echocardiography
Fractional ShorteningBaselineFractional shortening measured by M-mode cardiography

Secondary

MeasureTime frameDescription
Global Strain RateBaselineMyocardial deformation (a measure of heart contractility) measured by speckel tracking echocardiography
Systolic Myocardial Velocity During Systole (S')BaselineSystolic myocardial velocity during systole measured by tissue Doppler echocardiography
Early to Late Diastolic Filling RatioBaselineEarly to late diastolic filling ratio measured by tissue Doppler echocardiography
Myocardial Wall Velocity During Early DiastoleBaselineMyocardial wall velocity during early diastolemeasured by tissue Doppler imaging

Countries

United States

Participant flow

Participants by arm

ArmCount
Healthy Control
HIV-negative children born to healthy, HIV-negative women
30
Exposed to HIV/HAART
HIV-negative children exposed to HIV and HAART in utero
30
Total60

Baseline characteristics

CharacteristicHealthy ControlTotalExposed to HIV/HAART
Age, Continuous8 years
STANDARD_DEVIATION 2
8 years
STANDARD_DEVIATION 2
8 years
STANDARD_DEVIATION 3
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
22 Participants45 Participants23 Participants
Race (NIH/OMB)
More than one race
2 Participants3 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
6 Participants12 Participants6 Participants
Region of Enrollment
United States
30 participants60 participants30 participants
Sex: Female, Male
Female
11 Participants22 Participants11 Participants
Sex: Female, Male
Male
19 Participants38 Participants19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 300 / 30
serious
Total, serious adverse events
0 / 300 / 30

Outcome results

Primary

Fractional Shortening

Fractional shortening measured by M-mode cardiography

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Healthy ControlFractional Shortening36 percentage of full contractionStandard Deviation 5
Exposed to HIV/HAARTFractional Shortening37 percentage of full contractionStandard Deviation 7
Comparison: T-test to detect differences between groupsp-value: 0.46t-test, 2 sided
Primary

Left Ventricular Mass Index

left ventricular mass index measured by 2D echocardiography

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Healthy ControlLeft Ventricular Mass Index67 g/m2Standard Deviation 12
Exposed to HIV/HAARTLeft Ventricular Mass Index60 g/m2Standard Deviation 9
Comparison: T-test to detect differences between groupsp-value: 0.27t-test, 2 sided
Secondary

Early to Late Diastolic Filling Ratio

Early to late diastolic filling ratio measured by tissue Doppler echocardiography

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Healthy ControlEarly to Late Diastolic Filling Ratio2.1 ratio, unitlessStandard Deviation 0.5
Exposed to HIV/HAARTEarly to Late Diastolic Filling Ratio1.8 ratio, unitlessStandard Deviation 0.4
Comparison: T-test to detect differences between groupsp-value: 0.09t-test, 2 sided
Secondary

Global Strain Rate

Myocardial deformation (a measure of heart contractility) measured by speckel tracking echocardiography

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Healthy ControlGlobal Strain Rate-22.3 percentage of full deformationStandard Deviation 3.2
Exposed to HIV/HAARTGlobal Strain Rate-21.1 percentage of full deformationStandard Deviation 2.7
Comparison: T-test to detect differences between groupsp-value: 0.13t-test, 2 sided
Secondary

Myocardial Wall Velocity During Early Diastole

Myocardial wall velocity during early diastolemeasured by tissue Doppler imaging

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Healthy ControlMyocardial Wall Velocity During Early Diastole16.3 cm/sStandard Error 2.5
Exposed to HIV/HAARTMyocardial Wall Velocity During Early Diastole15.0 cm/sStandard Error 2.2
Comparison: T-test to detect differences between groupsp-value: 0.03t-test, 2 sided
Secondary

Systolic Myocardial Velocity During Systole (S')

Systolic myocardial velocity during systole measured by tissue Doppler echocardiography

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Healthy ControlSystolic Myocardial Velocity During Systole (S')9.3 cm/sStandard Deviation 1.1
Exposed to HIV/HAARTSystolic Myocardial Velocity During Systole (S')9.1 cm/sStandard Deviation 1.3
Comparison: T-test to detect differences between groupsp-value: 0.59t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026